Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
β
of holders' portfolios
13F filers
1
institution
Market cap
$293.6M
42M shares
52-week range
$4.48 β $13.22
29% from low
Sector
OPHTHALMIC GOODS
Exchange
NASDAQ
CS
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
www.rxsight.comNo one on the platform currently holds RXST.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 60,400 | $372.1K |
| Execution date | Ratio |
|---|---|
| 2006-09-21 | 9-for-1 |
No one on the platform has traded RXST yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
https://www.marketbeat.com/earnings/reports/2026-8-5-rxsight-inc-stock/ $RXST RxSight Earnings Transcript
View on StockTwits β$RXST Q2 '26 Earnings Results & Recap β’ Reported GAAP EPS of -$0.29 β’ Reported revenue of $33.74M up 0.31% YoY
View on StockTwits β$RXST New CEO and current one moving to a CMO role... Thoughts everyone?
View on StockTwits β$TARS Chief Commercial Officer left for a penny stock $RXST . Why does it say about TARS?π
View on StockTwits β$RXST Missed the Pre-Announced / confrims what the Doc's office had stated on headcount. With a Colab and +Rev's no help to PPS, it's early days. Boomers will be running to fix cataracts in LARGE Numbers. $STAA is pretty well flat Myopes can't see the writing on the wall, "very auspicious"
View on StockTwits β$RXST PSA part 2: YAG LASER (to remove scar tissue post LAL implant) CAUSES FLOATERS. This is a big ask - having done Vitrectomy to remove YEARS of Floaters last year, is what caused the early-onset cataracts. The LAL implant disclosures do NOT tell you "floaters" will occur. KNOWING at time of YAG that FLOATERS WILL BE BACK - after all this work to get to 20/15 vision - was frustrating. At the moment the large .75" walking-stick-floater in mid-vision has vanished. One lite small floater is hanging around, it should vanish soon - then ALL CLEAR is expected.
View on StockTwits β$RXST PSA: LAL implants started for me APRIL 2nd. Final adj's on 7/14 - I NOW SEE 20/15 in BOTH EYES. 2 x Lock-in appts due in next weeks. Stock-wise price is down from $6.64 while Doc's office saying headcount to RXST LAL patients has increased TEN FOLD. Next ER should tell the tale - I did not see many/any wearing the same Dark issue glasses as me since April. Overall GOOD TO KNOW : 1) "EVERYONE GETS DRY EYE" - you must be proactive to prevent this 2) "EVERYONE GETS SCAR TISSUE" - Doc will use YAG laser to remove 3) YAG LASER CAUSES DRY EYE - DO NOT LEAVE DOC'S OFFICE WITHOUT PREDNISONE and plenty of Refresh Drops 4) NO PREDNISONE POST YAG LASER WILL DELAY ADJUSMENTS - make sure your doc is on top of this 5)NO ADJUSTMENTS WILL BE MADE WITH DRY EYE 7) It is frustrating to have to wait FOUR MONTHS to complete, it is WORTH IT.
View on StockTwits β$RXST I'm gonna set an alert for new 52-week lows and just wait
View on StockTwits β$RXST Do you all feel their revenue miss was significant? Were people investing here hoping for better results?
View on StockTwits β$RXST so they are partnering with Alcon on a project....why the drop? I see this as a positive although not an immediate revenue stream ....
View on StockTwits β$RXST RXST - Alcon signs non-exclusive deal to co-develop adjustable PCIOLs w/ RxSight. RxSight gets $60M upfront, up to $140M in milestones, plus royalties. Watching
View on StockTwits βRecent $TICKER stream from stocktwits.com β refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $143M | +8.7% | $-1.05 | $-1.14β$-0.94 | β | 5 |
| 2027 | $150M | +4.7% | $-1.19 | $-1.36β$-1.01 | β | 5 |
| 2028 | $162M | +8.4% | $-0.80 | $-1.00β$-0.35 | β | 5 |
| 2029 | $149M | -8.0% | $0.00 | $0.00β$0.00 | β | 1 |
Forward consensus Β· growth is YoY vs the prior fiscal-year estimate Β· Fwd P/E at the current price Β· source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $-0.33 | $-0.29 | +12.0% |
| 2026-05-06 | $-0.30 | $-0.38 | -27.1% |
| 2026-02-25 | $-0.33 | $-0.22 | +34.3% |
| 2025-11-05 | $-0.19 | $-0.04 | +78.9% |
| 2025-08-07 | $-0.10 | $-0.08 | +20.0% |
| 2025-05-07 | $-0.22 | $-0.20 | +7.7% |
| 2025-02-25 | $0.10 | $0.03 | -70.0% |
| 2024-11-07 | $-0.25 |
| $-0.16 |
| +36.0% |
| $364M |
| β |
| KIDSOrthoPediatrics Corp. | $25.01 | +0.60% | $642M | β |
| NPCENeuroPace, Inc. | $14.51 | -0.34% | $495M | β |
Source: Financial Modeling Prep Β· peers by sector/industry